Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Hereditary Cancer Group, |
RCV001779207 | SCV001623542 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 3 | 2021-05-10 | criteria provided, single submitter | curation | |
Labcorp Genetics |
RCV001859339 | SCV002316447 | pathogenic | Fanconi anemia complementation group O | 2022-10-28 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the RAD51C protein in which other variant(s) (p.Arg258His) have been determined to be pathogenic (PMID: 20400963, 22167183, 26354865). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. Studies have shown that disruption of this splice site results in skipping of exon 5, but is expected to preserve the integrity of the reading-frame (PMID: 22006311, 24139550; Invitae). ClinVar contains an entry for this variant (Variation ID: 1098907). Disruption of this splice site has been observed in individual(s) with breast cancer and ovarian cancer (PMID: 29522266, 32107557). This variant is not present in population databases (gnomAD no frequency). This sequence change affects an acceptor splice site in intron 4 of the RAD51C gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in a shortened protein product. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002298949 | SCV002598984 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2022-09-02 | criteria provided, single submitter | clinical testing | Variant summary: RAD51C c.706-1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a canonical 3' acceptor site and creates a cryptic 3' acceptor site. However, these predictions have yet to be confirmed by functional studies. The variant was absent in 251368 control chromosomes. c.706-1G>A has been reported in the literature in individuals and families affected with Hereditary Breast And Ovarian Cancer Syndrome and colorectal cancer (Henn_2019, Yang_2020). Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Both classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. |